STOCK TITAN

Septerna, Inc. - SEPN STOCK NEWS

Welcome to our dedicated page for Septerna news (Ticker: SEPN), a resource for investors and traders seeking the latest updates and insights on Septerna stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Septerna's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Septerna's position in the market.

Rhea-AI Summary

Septerna (Nasdaq: SEPN) has successfully completed its upsized initial public offering, raising $331.2 million in gross proceeds. The clinical-stage biotechnology company, focused on GPCR oral small molecule drug discovery, sold 18,400,000 shares at $18.00 per share, including 2,400,000 additional shares from the full exercise of underwriters' option. Trading began on the Nasdaq Global Market on October 25, 2024, under ticker SEPN. J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities served as joint bookrunners for the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.32%
Tags
-
Rhea-AI Summary

Septerna (Nasdaq: SEPN) has announced the pricing of its upsized initial public offering of 16,000,000 shares at $18.00 per share. The company has granted underwriters a 30-day option to purchase up to an additional 2,400,000 shares. Trading is expected to begin on the Nasdaq Global Market on October 25, 2024. The IPO's gross proceeds are anticipated to reach $288.0 million, before deducting underwriting discounts and commissions. The offering is expected to close on October 28, 2024, with J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities serving as joint bookrunners.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Septerna (SEPN)?

The current stock price of Septerna (SEPN) is $25.525 as of November 6, 2024.

What is the market cap of Septerna (SEPN)?

The market cap of Septerna (SEPN) is approximately 1.1B.

Septerna, Inc.

Nasdaq:SEPN

SEPN Rankings

SEPN Stock Data

1.14B
42.00M
Biotechnology
Healthcare
Link
United States of America
South San Francisco